{"description":"Documents matching 'pexiganan'","count":4,"total_pages":1,"results":[{"title":"Grant of Interim Extension of the Term of U.S. Patent No. 5,912,231; LOCILEX® (pexiganan)","type":"Notice","abstract":"The United States Patent and Trademark Office has issued an order granting interim extension for a one-year interim extension of the term of U.S. Patent No. 5,912,231.","document_number":"2017-10964","html_url":"https://www.federalregister.gov/documents/2017/05/26/2017-10964/grant-of-interim-extension-of-the-term-of-us-patent-no-5912231-locilex-pexiganan","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2017-05-26/pdf/2017-10964.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2017-10964.pdf?1495716415","publication_date":"2017-05-26","agencies":[{"raw_name":"DEPARTMENT OF COMMERCE","name":"Commerce Department","id":54,"url":"https://www.federalregister.gov/agencies/commerce-department","json_url":"https://www.federalregister.gov/api/v1/agencies/54","parent_id":null,"slug":"commerce-department"},{"raw_name":"Patent and Trademark Office","name":"Patent and Trademark Office","id":402,"url":"https://www.federalregister.gov/agencies/patent-and-trademark-office","json_url":"https://www.federalregister.gov/api/v1/agencies/402","parent_id":54,"slug":"patent-and-trademark-office"}],"excerpts":"the patent. \n On May 9, 2017, Scripps Research Institute, the patent owner of record, timely filed an application under 35 U.S.C. 156(d)(5) for a second interim extension of the term of U.S. Patent No. 5,912,231. The patent claims a composition of the active ingredient <span class=\"match\">pexiganan</span> of the human drug product LOCILEX®. The application for patent term extension indicates that New Drug Application (NDA) 29-930 was submitted to the Food and Drug Administration (FDA) on July 24, 1998. \n Review of the patent term extension application indicates that, except"},{"title":"Grant of Interim Extension of the Term of U.S. Patent No. 5,912,231; LOCILEX® (pexiganan)","type":"Notice","abstract":"The United States Patent and Trademark Office has issued an order granting interim extension under 35 U.S.C. 156(d)(5) for a one- year interim extension of the term of U.S. Patent No. 5,912,231.","document_number":"2016-13764","html_url":"https://www.federalregister.gov/documents/2016/06/10/2016-13764/grant-of-interim-extension-of-the-term-of-us-patent-no-5912231-locilex-pexiganan","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2016-06-10/pdf/2016-13764.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2016-13764.pdf?1465476529","publication_date":"2016-06-10","agencies":[{"raw_name":"DEPARTMENT OF COMMERCE","name":"Commerce Department","id":54,"url":"https://www.federalregister.gov/agencies/commerce-department","json_url":"https://www.federalregister.gov/api/v1/agencies/54","parent_id":null,"slug":"commerce-department"},{"raw_name":"United States Patent and Trademark Office","name":"Patent and Trademark Office","id":402,"url":"https://www.federalregister.gov/agencies/patent-and-trademark-office","json_url":"https://www.federalregister.gov/api/v1/agencies/402","parent_id":54,"slug":"patent-and-trademark-office"}],"excerpts":"date of the patent. \n On May 26, 2016, Scripps Research Institute, the patent owner of record, timely filed an application under 35 U.S.C. 156(d)(5) for an interim extension of the term of U.S. Patent No. 5,912,231. The patent claims a composition of the active ingredient <span class=\"match\">pexiganan</span> of the human drug product LOCILEX®. The application for patent term extension indicates that New Drug Application (NDA) 29-930 was submitted to the Food and Drug Administration (FDA) on July 24, 1998. \n Review of the patent term extension application indicates that, except"},{"title":"Anti-Infective Drugs Advisory Committee; Notice of Meeting","type":"Notice","abstract":null,"document_number":"99-3108","html_url":"https://www.federalregister.gov/documents/1999/02/09/99-3108/anti-infective-drugs-advisory-committee-notice-of-meeting","pdf_url":"https://www.govinfo.gov/content/pkg/FR-1999-02-09/pdf/99-3108.pdf","public_inspection_pdf_url":null,"publication_date":"1999-02-09","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"301-827-7001, or FDA Advisory Committee \nInformation Line, 1-800-741-8138 (301-443-0572 in the Washington, DC \narea), code 12530. Please call the Information Line for up-to-date \ninformation on this meeting.\n    Agenda: The committee will discuss new drug application 20-930, \n<span class=\"match\">pexiganan</span> acetate 1 percent topical cream (Magainin Pharmaceuticals) \nfor treatment of infections in diabetic foot ulcers.\n\n[[Page 6368]]\n\n    Procedure: Interested persons may present data, information, or \nviews, orally or in writing, on issues pending before the committee. \nWritten"},{"title":"Advice Concerning the Addition of Certain Pharmaceutical Products and Chemical Intermediates to the Pharmaceutical Appendix to the HTS","type":"Notice","abstract":"Following receipt on December 23, 1998, of a request from the United States Trade Representative (USTR), the Commission instituted investigation No. 332-402, Advice Concerning the Addition of Certain Pharmaceutical Products and Chemical Intermediates to the Pharmaceutical Appendix to the Harmonized Tariff Schedule of the United States, under section 332(g) of the Tariff Act of 1930 (19 U.S.C. 1332(g)). At the request of USTR, the Commission will provide: (1) A summary description of the products contained in the existing Pharmaceutical Appendix and the modifications to be made to that Appendix; (2) an explanation of the relationship of the various elements in the Appendix to the HTS; and (3) estimates of current U.S. imports, and where possible, U.S. exports of the products included in the Pharmaceutical Appendix and the proposed additions to the Appendix, based on product groupings as necessary. The Commission will submit its report to the USTR no later than April 1, 1999.","document_number":"99-1342","html_url":"https://www.federalregister.gov/documents/1999/01/21/99-1342/advice-concerning-the-addition-of-certain-pharmaceutical-products-and-chemical-intermediates-to-the","pdf_url":"https://www.govinfo.gov/content/pkg/FR-1999-01-21/pdf/99-1342.pdf","public_inspection_pdf_url":null,"publication_date":"1999-01-21","agencies":[{"raw_name":"INTERNATIONAL TRADE COMMISSION","name":"International Trade Commission","id":262,"url":"https://www.federalregister.gov/agencies/international-trade-commission","json_url":"https://www.federalregister.gov/api/v1/agencies/262","parent_id":null,"slug":"international-trade-commission"}],"excerpts":"Palinavir     154612-39-2\nPalonosetron     135729-56-5\nPamaqueside     150332-35-7\nPamiteplase     151912-42-4\nParicalcitol     131918-61-1\nPegmusirudin     186638-10-8\nPeldesine     133432-71-0\nPelubiprofen      69956-77-0\nPemetrexed     137281-23-3\nPerifosine     157716-52-4\n<span class=\"match\">Pexiganan</span>     172820-23-4\nPibutidine     103922-33-4\nPifonakin     112721-39-8\nPleconaril     153168-05-9\nPralmorelin     158861-67-7\nPramlintide     151126-32-8\nPranazepide     150408-73-4\nPregabalin     148553-50-8\nPrucalopride     179474-81-8\nPumaprazole     158364-59-1\nQuetiapine"}]}